Symptom Control Satisfaction With Proton Pump Inhibitor Regimen

Status Completed

Clinical Trial Summary

The overall aim of this study is to assess if patients with persistent gastroesophageal reflux disease (GERD) symptoms receiving sub-optimal omeprazole dosing experience improvement in GERD symptoms when prescribed an optimal dosing regimen. The optimal dosing regimen is defined as taking omeprazole 30 minutes prior to the first meal of the day.

Clinical Trial Description

GERD remains a common gastrointestinal complaint, resulting in 6% of outpatient visits. The economic burden is significant with direct costs exceeding $12 billion/year and indirect cost as high as $75 billion/year. The primary aim of this study was determine whether a brief educational intervention optimizing proton pump inhibitor (PPI) dosing would reduce GERD symptoms using the gastroesophageal reflux disease symptom assessment scale (GSAS) questionnaire. Further, secondary analysis would utilize the results of the trial and combine them with costs related to uncontrolled GERD to estimated the potential economic impact. ;

Study Design

Related Conditions & MeSH terms

Heartburn

Clinical Trial Details

NCT number	NCT02623816
Study type	Interventional
Source	MetroHealth Medical Center
Contact
Status	Completed
Phase	Phase 4
Start date	August 2014
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06094062` - Smartphone App-assisted PPI	N/A
Completed	`NCT00481949` - Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo	N/A
Completed	`NCT04560595` - Remote Guided Caffeine Reduction	N/A
Recruiting	`NCT01696734` - Domperidone in Treating Patients With Gastrointestinal Disorders	Phase 3
Recruiting	`NCT02105090` - Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy	Phase 4
Completed	`NCT01338077` - Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease	Phase 3
Completed	`NCT01005251` - Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI	Phase 2
Terminated	`NCT00536328` - What is the Predictive Value of the Reflux Impact Scale	N/A
Completed	`NCT00382577` - Efficacy and Safety of Itopride vs Placebo in Heartburn	Phase 3
Completed	`NCT00236197` - E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers	Phase 3
Completed	`NCT00236184` - E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers	Phase 3
Completed	`NCT00236392` - A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)	Phase 3
Completed	`NCT04153552` - Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn	N/A
Recruiting	`NCT06075082` - The Effect of the LEFT Smartwatch App as Sleep Positional Therapy for Nocturnal Gastroesophageal Reflux Symptoms.	N/A
Completed	`NCT05247333` - Implementation of a Minor Ailment Service in Community Pharmacy Practice	N/A
Recruiting	`NCT02277886` - Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances	Phase 4
Completed	`NCT01249651` - To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole	Phase 4
Completed	`NCT00588939` - Confocal Laser Microscopy in Non Erosive Reflux Disease	N/A
Completed	`NCT00206024` - Acid-Associated Heartburn Symptoms and Dose of Esomeprazole	Phase 4
Recruiting	`NCT05976165` - A Study of Breath Testing for Small Intestinal Bacterial Overgrowth	N/A